Imagine a tiny, smart pill that you swallow to check your gut health from the inside. Instead of invasive hospital procedures, this pill sends health data to your phone via Bluetooth, which then uploads it to a cloud for a doctor to see. It's like having a small, temporary sensor in your stomach that tells the doctor exactly what's happening without needing a surgery.
Gastrointestinal diseases like GERD are often underdiagnosed because current diagnostic tools are invasive, outdated, and hard to access, especially in low-resource regions.
A smart, ingestible capsule prototype, a Bluetooth-connected smartphone application, and a digital cloud platform for AI-aided clinical interpretation.
If you are a medical device company dealing with outdated, invasive diagnostic tools — this project developed a smart, ingestible capsule that monitors GI physiology and transmits data via Bluetooth. This allows for a shift from analogue diagnostics to a digital, patient-centered tool.
If you are a digital health provider dealing with a lack of objective data for remote patients — this project developed a cloud platform and smartphone app that integrates physiological data with patient-reported outcomes. This enables clinicians to personalize tests and receive AI-aided interpretations remotely.
If you are a clinic operator dealing with limited healthcare infrastructure — this project developed a universal e-health solution that brings advanced GI diagnostics to remote areas. It reduces the need for expensive, high-end hospital equipment for GERD screening.
Based on available project data, specific pricing is not mentioned, but the project aims to demonstrate cost savings using GERD as a clinical target.
The project aims to shift GI diagnostics from an unscalable analogue version to a digital e-health tool, suggesting a focus on scalability through cloud and smartphone integration.
Based on available project data, specific IP and licensing terms are not provided, though the consortium includes 7 industry partners.
The system integrates via a smartphone app and a digital cloud platform, allowing clinicians to personalize tests and receive AI-aided results.
The project period runs from 2022-05-01 to 2027-04-30, with clinical trials currently in preparation.
The consortium is heavily industry-weighted with a 64% industry ratio, comprising 7 industrial partners (including 3 SMEs) across 7 countries. This strong commercial presence, combined with the coordination by a scientific foundation and the inclusion of partners from France, Ukraine, and Kenya, indicates a clear strategy for global market entry and practical clinical application rather than pure academic research.
Contact Fondation de Cooperation Scientifique in France
Contact us to explore licensing opportunities for the eCAP smart capsule technology.
